#fatty liver disease

New guidelines recommend focusing on healthy foods but don’t restrict added sugars or alcohol as much as some experts had hoped.

If passed, the law would boost liver disease research and create a national strategy to tackle non-alcoholic steatohepatitis.

Fat in the liver can lead to health complications, including cirrhosis and liver cancer.

Developing treatments for fatty liver disease has proved challenging, and there are currently no approved medications.

Optimal treatment for fatty liver disease may involve combining drugs with different mechanisms of action.

Many people with fatty liver disease have obesity, diabetes and other metabolic conditions.

As people with HIV live longer thanks to effective antiretroviral treatment, they are prone to a host of additional health problems.

As with HIV-negative individuals, non-alcoholic fatty liver disease is tied to diabetes and irregular blood lipids in those with HIV.

Fatty liver disease is tied to risk of metabolic problems in people with HIV.

The injectable hormone helps reduce inflammation and fibrosis associated with NAFLD in this population.

Non-alcoholic steatohepatitis, the more severe form of non-alcoholic fatty liver disease, is highly prevalent in the HIV population.

Researchers call for greater use of noninvasive measures of fatty liver disease in this population to identify those at risk.

About a quarter of people taking a higher dose of Ocaliva saw an improvement in liver fibrosis.

The application is based on study results showing that up to 23% of treated patients saw an improvement in liver fibrosis.

Study finds people who took daily aspirin had a lower risk of NASH and advanced liver scarring.